Ware Discusses with Reuters the Future of Non-Disclosure Agreements in Sexual Harassment and Misconduct Cases
19 December 2017
Of Counsel Dabney Ware told Reuters in the article “Sexual Misconduct Outcry Makes U.S. Lawyers Rethink Confidentiality” that non-disclosure agreements will likely be on the wane in workplace sexual harassment settlements and that future confidentiality agreements might cover only the names of the parties and the amount paid in the settlement, while allowing allegations to be made public.
Ware said she expects non-disclosure agreements to continue to be used in less egregious cases, or when investigations into harassment claims are inconclusive. “We’re still going to have places where it seems appropriate to keep things confidential, but it’s going to be a lot more limited,” she said.
Ware said she expects non-disclosure agreements to continue to be used in less egregious cases, or when investigations into harassment claims are inconclusive. “We’re still going to have places where it seems appropriate to keep things confidential, but it’s going to be a lot more limited,” she said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”